Telmisartan plus amlodipine single-pill combination for the management of hypertensive patients with a metabolic risk profile (added-risk patients)

References

• WHO. Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risk. Geneva, Switzerland: World Health Organization, 2009
   Google Scholar
• Ezzati M, Oza S, Danaei G, Murray CJ. Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States. Circulation 2008;117:905-14
   PubMed Web of Science ®Google Scholar
• Sharma AM, Weir MR. The role of angiotensin receptor blockers in diabetic nephropathy. Postgrad Med 2011;123:109-21
   PubMed Web of Science ®Google Scholar
• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14
   PubMed Web of Science ®Google Scholar
• Berghofer A, Pischon T, Reinhold T, et al. Obesity prevalence from a European perspective: a systematic review. BMC Public Health 2008;8:200
   PubMed Web of Science ®Google Scholar
• Banegas JR, Segura J, Ruilope LM, et al. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 2004;43:1338-44
   PubMed Web of Science ®Google Scholar
• Adelman RD. Obesity and renal disease. Curr Opin Nephrol Hypertens 2002;11:331-5
   PubMed Web of Science ®Google Scholar
• Yanai H, Tomono Y, Ito K, et al. The underlying mechanisms for development of hypertension in the metabolic syndrome. Nutr J 2008;7:10
   PubMed Web of Science ®Google Scholar
• Grundy SM, Hansen B, Smith SC Jr, et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Arterioscler Thromb Vasc Biol 2004;24:e19-24
   PubMed Web of Science ®Google Scholar
• Mancia G, De BG, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53
   Google Scholar
• The IDF consensus worldwide definition of the metabolic syndrome. 2012
   Google Scholar
• Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med 2011;9:48
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52
   PubMed Web of Science ®Google Scholar
• Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85
   PubMed Web of Science ®Google Scholar
• Denardo SJ, Messerli FH, Gaxiola E, et al. Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]). Am J Cardiol 2010;106:498-503
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
   PubMed Web of Science ®Google Scholar
• Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. J Clin Hypertens (Greenwich) 2011;13:146-54
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31
   PubMed Web of Science ®Google Scholar
• Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049-51
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
   PubMed Web of Science ®Google Scholar
• Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375:1173-81
   PubMed Web of Science ®Google Scholar
• White WB, Littlejohn TW, Majul CR, et al. Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. Blood Press Monit 2010;15:205-12
   PubMed Web of Science ®Google Scholar
• Littlejohn III TW, Majul CR, Olvera R, et al. Results of treatment with telmisartan–amlodipine in hypertensive patients. J Clin Hypertens (Greenwich) 2009;11:207-13
   PubMed Web of Science ®Google Scholar
• Littlejohn III TW, Majul CR, Olvera R, et al. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 × 4 factorial study. Postgrad Med 2009;121:5-14
   Web of Science ®Google Scholar
• WHO. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1995;854:1-452
   PubMed Web of Science ®Google Scholar
• WHO. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-63
   PubMed Web of Science ®Google Scholar
• JASSO. Guidelines for diagnosis and treatment of obesity and its comorbidities. 1999
   Google Scholar
• Neutel JM, Mancia G, Black HR, et al. Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study. J Clin Hypertens (Greenwich) 2012;14:206-15
   PubMed Web of Science ®Google Scholar
• Sharma AM, Bakris G, Neutel JM, et al. Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial. Clin Ther. 2012;34:537--51
   Google Scholar
• Boehringer Ingelheim International GmbH. A randomised, double-blind trial to compare telmisartan 40 mg plus amlodipine 5 mg fixed-dose combination to amlodipine 5 mg monotherapy in patients not controlled with amlodipine 5 mg (clinical trial results database; trial no. 1235.13). 2011
   Google Scholar
• Boehringer Ingelheim International GmbH. A randomised, double-blind trial to compare telmisartan 40 mg plus amlodipine 5 mg fixed-dose combination to telmisartan 40 mg monotherapy in patients not controlled with telmisartan 40 mg (clinical trial results database; trial no. 1235.14). 2011
   Google Scholar
• Neldam S, Lang M, Jones R. Telmisartan and amlodipine single-pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: results of the TEAMSTA-5 study. J Clin Hypertens (Greenwich) 2011;13:459-66
   PubMed Web of Science ®Google Scholar
• Neldam S, Edwards C, Jones R. Switching patients with uncontrolled hypertension on amlodipine 10 mg to single-pill combinations of telmisartan and amlodipine: results of the TEAMSTA-10 study. Curr Med Res Opin 2011;27:2145-53
   PubMed Web of Science ®Google Scholar
• Neldam S, Edwards C, Lang M, Jones R. Long-term tolerability and efficacy of single-pill combinations of telmisartan 40–80 mg plus amlodipine 5 or 10 mg in patients not initially controlled on amlodipine 5 or 10 mg: open-label, long-term follow-ups of the TEAMSTA-5 and TEAMSTA-10 studies. Curr Therapeut Res 2012;73:65-84
   PubMed Web of Science ®Google Scholar
• Sharma A, Bagchi A, Kinagi SB, et al. Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension. Clin Ther 2007;29:2667-76
   PubMed Web of Science ®Google Scholar
• Faruqui AA. Evaluation of safety and efficacy of telmisartan–amlodipine combination in treating hypertension. J Indian Med Assoc 2008;106:612-14,624
   PubMedGoogle Scholar
• Yuan H, Cai J, Huang Z. Amlodipine plus telmisartan or amiloride for hypertensive patients: focus on effects on metabolic profiles. Presented at the American Society of Hypertension 26th Annual Scientific Meeting and Exposition, New York, USA, 2011. Poster PO-160. J Clin Hypertens 2011;13(Suppl 1):A80
   Google Scholar
• Cai J, Huang Z, Cui R, et al. Amlodipine plus telmisartan or amiloride for hypertension in moderate and high-risk patients: a 24-week observation. Presented at the American Society of Hypertension 26th Annual Scientific Meeting and Exposition, New York, USA, 2011. Poster PO-161. J Clin Hypertens 2011;13(Suppl 1):A80
   Google Scholar
• Wang W, Ma L, Zhang Y, et al. The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics. J Hum Hypertens 2011;25:271-7
   PubMed Web of Science ®Google Scholar
• Ma L, Wang W, Zhao Y, et al. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study. Am J Cardiovasc Drugs 2012;12:137-42
   Google Scholar
• Fogari R, Derosa G, Zoppi A, et al. Effect of telmisartan–amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens 2007;20:417-22
   PubMed Web of Science ®Google Scholar
• Faruqui AA, Kadam GG, Joshi C. Treatment of hypertension: postmarketing surveillance study results of telmisartan monotherapy, fixed dose combination of telmisartan + hydrochlorothiazide/amlodipine. J Indian Med Assoc 2009;107:730-3
   PubMedGoogle Scholar
• Guthrie RM, Dahlof B, Jamerson KA, et al. Efficacy and tolerability of telmisartan plus amlodipine in added-risk hypertensive patients. Curr Med Res Opin 2011;27:1995-2008
   PubMed Web of Science ®Google Scholar
• Littlejohn 3rd TW, Ruilope LM, Chrysant SG, et al. Efficacy of telmisartan in combination with amlodipine in obese hypertensive patients: sub-analysis from a factorial design study. 2009. Presented at the 19th Scientific Meeting of the European Society of Hypertension. Milan, Italy, 2009
   Google Scholar
• Littlejohn 3rd TW, Mancia G, Christensen S, et al. Telmisartan and amlodipine in combination are effective at lowering 24-h blood pressure in diabetic and obese hypertensive patients: findings of an ABPM sub-study. 2009. Presented at the 19th Scientific Meeting of the European Society of Hypertension. Milan, Italy, 2009
   Google Scholar
• Moen MD. Telmisartan/amlodipine: single-pill combination in hypertension. Am J Cardiovasc Drugs 2010;10:401-12
   PubMed Web of Science ®Google Scholar
• Littlejohn 3rd TW, Ruilope LM, Raskin P, et al. Telmisartan in combination with amlodipine provides a highly effective and well-tolerated treatment option for hypertensive patients with diabetes: sub-analysis from a factorial design study. 2009. Presented at the 19th Scientific Meeting of the European Society of Hypertension. Milan, Italy, 2009
   Google Scholar
• Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28
   PubMed Web of Science ®Google Scholar
• MICARDIS. Summary of Product Characteristics. 2011. Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000209/WC500027641.pdf
   Google Scholar
• Liu W, Wang W, Song SW, et al. Synergism of telmisartan and amlodipine on blood pressure reduction and cardiorenal protection in hypertensive rats. J Cardiovasc Pharmacol 2011;57:308-16
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008;30:587-604
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Lee J, Melino M, et al. Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. J Hum Hypertens 2010;24:730-8
   PubMed Web of Science ®Google Scholar
• Bakris GL. CON: blood pressure treatment goal for patients with diabetes should be < 130/80 mm Hg. J Clin Hypertens (Greenwich) 2011;13:263-5
   PubMed Web of Science ®Google Scholar
• Mancia G, Schumacher H, Redon J, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation 2011;124:1727-36
   PubMed Web of Science ®Google Scholar
• Haller H, Ito S, Izzo JL Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:907-17
   PubMed Web of Science ®Google Scholar
• Messerli FH, Panjrath GS. The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol 2009;54:1827-34
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-83
   PubMed Web of Science ®Google Scholar
• Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359:1225-37
   PubMed Web of Science ®Google Scholar
• Bangalore S, Messerli FH, Wun CC, et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J 2010;31:2897-908
   PubMed Web of Science ®Google Scholar
• Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006;144:884-93
   PubMed Web of Science ®Google Scholar
• Sleight P. Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor. J Hypertens Suppl 2009;27:S23-S29
   PubMedGoogle Scholar
• Albers AR, Krichavsky MZ, Balady GJ. Stress testing in patients with diabetes mellitus: diagnostic and prognostic value. Circulation 2006;113:583-92
   PubMed Web of Science ®Google Scholar
• Kurtz TW, Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens Res 2009;32:826-34
   PubMed Web of Science ®Google Scholar
• Barzilay JI, Gao P, Ryden L, et al. Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study. Diabetes Care 2011;34:1902-7
   PubMed Web of Science ®Google Scholar
• Suksomboon N, Poolsup N, Prasit T. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes. J Clin Pharm Ther 2012;37:319-27
   Google Scholar
• Bekki H, Yamamoto K, Sone M, et al. Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension. Clin Cardiol 2011;34:261-5
   PubMed Web of Science ®Google Scholar
• Makani H, Bangalore S, Romero J, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate – a meta-analysis of randomized trials. J Hypertens 2011;29:1270-80
   PubMed Web of Science ®Google Scholar
• Makani H, Bangalore S, Romero J, et al. Effect of renin–angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med 2011;124:128-35
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Maffioli P, et al. Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients. Expert Opin Pharmacother 2011;12:2441-8
   PubMed Web of Science ®Google Scholar
• McGill JB. Improving microvascular outcomes in patients with diabetes through management of hypertension. Postgrad Med 2009;121:89-101
   PubMed Web of Science ®Google Scholar